First US Strategic Partnership for OmnySense
OmnySense is an Israeli MedTech startup that has developed a unique cloud-based health information system that enables the health of patients at home to be
Texas Medical Tech Invests in Olive Diagnostics Toilet-Mounted Urinalysis Device
Olive Diagnostics, a MedTech company transforming at-home urinalysis testing with a passive, continuous home monitoring system mounted on a toilet, has received a substantial investment
Alpha Tau Medical Reports Positive Skin Cancer Results in First US Clinical Trial
Jerusalem based Alpha Tau Medical Ltd. TM (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy, announced that all ten patients in its US
Gamida Cell Submitting Biologics License Application to the U.S. FDA
Gamida Cell Ltd. (Nasdaq:GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, received a positive meeting correspondence from the
Israel’s OrCam Wins CES 2022 Innovation Award for 3rd Consecutive Year
OrCam Technologies, the Jerusalem-based firm known for its AI-driven vision assistance technology, beat out over 1,800 products to receive its third consecutive win at the
GALS BIO is Crowdfunding its TULIPON, the Smart Tampon
For the past month, GalsBio has been carrying out a crowdfunding campaign for the second round of funding for the Tulipon – a smart next-generation
Bio Park-Jerusalem’s Largest Biopharma and MedTech Park is Open for Business!
Bio Park’s vision is to create the largest industrial bio-park (Existing: 40K sqm and planned 300 K sqm) with a human-centric village, offering: Offices, labs,
SpliSense Granted FDA & EMA Orphan Drug Designation to SPL84-23-1 for Cystic Fibrosis Treatment
Jerusalem-based Splisense, a biopharmaceutical company developing transformative mRNA altering therapies for cystic fibrosis (CF) and other pulmonary diseases, has been granted orphan drug designation (ODD)
Cell Cure Neurosciences enters exclusive worldwide collaboration with Genentech (Roche Group) for Ocular Disorders
Lineage Cell Therapeutics, Inc. (NYSE and TASE: LCTX) and its subsidiary Cell Cure Neurosciences, Ltd, recently entered into an exclusive worldwide collaboration and license agreement
